Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Best Pract Res Clin Obstet Gynaecol
; 89: 102350, 2023 Jul.
Article
em En
| MEDLINE
| ID: mdl-37320996
ABSTRACT
This non-interventional study compared the effectiveness of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) (21 ratio) versus r-hFSH alone for ovarian stimulation (OS) during assisted reproductive technology treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register (D·I·R). Numerically higher clinical pregnancy (29.8% [95% CI 28.2, 31.6] vs. 27.8% [26.5, 29.2]) and live birth (20.3% [18.7, 21.8] vs. 18.0% [16.6, 19.4]) rates were observed with r-hFSHr-hLH versus r-hFSH alone. The treatment effect was consistently higher for r-hFSHr-hLH compared with r-hFSH alone in terms of clinical pregnancy (relative risk [RR] 1.16 [1.05, 1.26]) and live birth (RR 1.16 [1.02, 1.31]) in a post-hoc analysis of women with 5-14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of r-hFSHr-hLH for OS in women aged 35-40 years with normal ovarian reserve.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hormônio Luteinizante
/
Hormônio Foliculoestimulante Humano
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article